SBIR/STTR Research Award
Prevention of Children's Tympanostomy Tube Otorrhea
Award amount
$159,277Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- O-RAY PHARMA
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- RKCLYRGPNAP8
- Solicitation number
- PA14-071
- Topic code
- NIDCD
Research abstract
DESCRIPTION (provided by applicant): Otitis media (infection of the middle ear space) is one of the most common diseases of childhood. Myringotomy with tympanostomy tube (TT) insertion is the most common operation performed on children in the United States. Otorrhea is the most common complication following tube insertion and can occur in up to 17% of ears receiving TT and is often associated with active infection. Current treatments involve the administration of antibiotic or antibiotic/steroid drops twicea day for 14 days. Though this decreases the incidence of infection, there are issues with patient compliance and temporary conductive hearing loss in the children. An enhanced treatment option would improve treatment efficacy, increase patient compliance, and eliminate the temporary hearing loss. This Phase I SBIR proposal involves the fabrication of therapeutic treatments for otitis media associated with tympanostomy tubes in children. The specific aims of this proposal present a roadmap towards the
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- IND-enabling Preclinical Development of Sustained Release Inner Ear Delivery of Corticosteroid
- Prevention of Children's Tympanostomy Tube Otorrhea
- Inner ear therapeutics for sustained treatment of autoimmune inner ear disease
- Intratympanic delivery of biologics for treatment of autoimmune inner ear disease
- Sustained Release Inner Ear Delivery of Corticosteroid
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Cell type-specific gene therapy approach for TOMT-linked congenital hearing loss
- Real time speech enhancement/noise reduction for the hearing impaired
- Development of a Navigation-Based Insertion Tool for Trajectory Optimization during Cochlear Implantation
- Phonocath - An endovascular medical device to objectively evaluate Pulsatile Tinnitus
- Smartphone based custom-fit and low-cost hearing aids manufacturing system
Research funding history
9 SBIR/STTR records share this UEI (2010–2022). Reported award amounts total $6,441,813. Reported amounts are not federal obligations.
Phases: Phase II, Phase I, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services